SPOTLIGHT -
EP. 1: Understanding Tropomyosin Receptor Kinase Inhibitors
EP. 2: Preliminary Safety/Efficacy Data for Larotrectinib
EP. 3: How Will Larotrectinib Be Used?
EP. 4: Entrectinib's Value as a TRK Inhibitor
EP. 5: TRK Inhibition's Potential Role in Clinical Practice
EP. 6: Next-Generation Sequencing for TRK Inhibition
EP. 7: Challenges With NGS for TRK Inhibition
EP. 8: NGS Across Tumor Types for TRK Inhibition
EP. 9: Optimal Use of NGS for TRK Inhibition
EP. 10: TRK Inhibition: Ongoing Challenges
EP. 11: Moving Forward With TRK Inhibition
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
